Jason Kwah, MD, MSc

2025

• High-Risk Penicillin Reaction Flags in the Medical Record

  Novotny S, Elmansy L, Kwah J, Liao J, Wong K, Stone C, Belmont A. High-Risk Penicillin Reaction Flags in the Medical Record. JAMA Network Open 2025, 8: e2549081. PMCID: PMC12717615, DOI: 10.1001/jamanetworkopen.2025.49081.

  Peer-Reviewed Original Research

  Citations

  Altmetric

  Concepts

• SA82 Real-World Findings From the Provent Study of Dupilumab Therapy for Severe Asthma: 2-Year Analysis

  Lommatzsch M, Korn S, Schmidt O, Timmermann H, Gappa M, Watz H, Kwah J, LEDANOIS O, Nischan N, Hahn M, Heimann A. SA82 Real-World Findings From the Provent Study of Dupilumab Therapy for Severe Asthma: 2-Year Analysis. Value In Health 2025, 28: s661-s662. DOI: 10.1016/j.jval.2025.09.3023.

  Peer-Reviewed Original Research

• BASELINE TYPE 2 BIOMARKERS AS PREDICTORS OF MULTICOMPONENT CLINICAL REMISSION FOLLOWING DUPILUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ASTHMA

  CANONICA G, PAVORD I, COUILLARD S, BRUSSELLE G, CASTRO M, BOURDIN A, ALTINCATAL A, KWAH J, LEDANOIS O, DE LLANO L. BASELINE TYPE 2 BIOMARKERS AS PREDICTORS OF MULTICOMPONENT CLINICAL REMISSION FOLLOWING DUPILUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ASTHMA. Chest 2025, 168: a40-a43. DOI: 10.1016/j.chest.2025.07.022.

  Peer-Reviewed Original Research

  Concepts

• CO178 Dupilumab Improves Health-Related Quality Of Life And Asthma Control In Patients With And Without Coexisting Type 2 Conditions: Results From The RAPID Study

  Mosnaim G, Price D, Côté A, Plaza V, Xia C, Awad H, Kwah J. CO178 Dupilumab Improves Health-Related Quality Of Life And Asthma Control In Patients With And Without Coexisting Type 2 Conditions: Results From The RAPID Study. Value In Health 2025, 28: s56. DOI: 10.1016/j.jval.2025.04.263.

  Peer-Reviewed Original Research

  Concepts

• CO143 Outcomes In Patients With Asthma and Coexisting Allergic Rhinitis Who Started Dupilumab Treatment In Real-World Clinical Practice: A RAPID Registry Study

  Côté A, Muñoz X, Price D, Mosnaim G, Xia C, Awad H, Kwah J. CO143 Outcomes In Patients With Asthma and Coexisting Allergic Rhinitis Who Started Dupilumab Treatment In Real-World Clinical Practice: A RAPID Registry Study. Value In Health 2025, 28: s49. DOI: 10.1016/j.jval.2025.04.228.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• Dupilumab Improves Health-related Quality of Life and Asthma Control in Patients With and Without Coexisting Type 2 Conditions: Results From the RAPID Study

  Cote A, Mosnaim G, Lugogo N, Price D, Plaza V, Changming X, Awad H, Kwah J. Dupilumab Improves Health-related Quality of Life and Asthma Control in Patients With and Without Coexisting Type 2 Conditions: Results From the RAPID Study. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a1399-a1399. DOI: 10.1164/ajrccm.2025.211.abstracts.a1399.

  Peer-Reviewed Original Research

  Altmetric

  Concepts

• Elevated inflammatory type 2 biomarkers at baseline predict multicomponent clinical remission following dupilumab treatment in patients with moderate-to-severe asthma

  De Llano L, Guilleminault L, Canonica G, Pavord I, Couillard S, Porsbjerg C, Brusselle G, Castro M, Bourdin A, Altincatal A, Kwah J, Ledanois O. Elevated inflammatory type 2 biomarkers at baseline predict multicomponent clinical remission following dupilumab treatment in patients with moderate-to-severe asthma. Revue Française D'Allergologie Et D'Immunologie Clinique 2025, 65: 104323. DOI: 10.1016/j.reval.2025.104323.

  Peer-Reviewed Original Research

  Concepts

• Evaluating Penicillin Allergy Clinical Decision-Making Tools to Enhance Penicillin Allergy De-labeling

  Su C, Belmont A, Kuster J, Liao J, Kwah J. Evaluating Penicillin Allergy Clinical Decision-Making Tools to Enhance Penicillin Allergy De-labeling. The Journal Of Allergy And Clinical Immunology 2025, 155: ab5. DOI: 10.1016/j.jaci.2024.12.021.

  Peer-Reviewed Original Research

• Baseline Characteristics Associated With Multicomponent Clinical Remission Following Dupilumab Treatment In Patients With Moderate-To-Severe Asthma

  Canonica G, de Llano L, Pavord I, Couillard S, Porsbjerg C, Brusselle G, Castro M, Peters A, Bourdin A, Altincatal A, Kwah J, Ledanois O. Baseline Characteristics Associated With Multicomponent Clinical Remission Following Dupilumab Treatment In Patients With Moderate-To-Severe Asthma. The Journal Of Allergy And Clinical Immunology 2025, 155: ab20. DOI: 10.1016/j.jaci.2024.12.068.

  Peer-Reviewed Original Research

  Concepts

• Real-World Effectiveness of Dupilumab vs Omalizumab, Benralizumab, and Mepolizumab on Lung Function Improvement in Severe Asthma Patients: Findings from the EU-ADVANTAGE Study

  Bourdin A, Canonica G, Virchow J, Borsos K, Stanford R, Ledanois O, Kwah J, Ge W, Huynh L, Duh M, Boca A, Cheng W. Real-World Effectiveness of Dupilumab vs Omalizumab, Benralizumab, and Mepolizumab on Lung Function Improvement in Severe Asthma Patients: Findings from the EU-ADVANTAGE Study. The Journal Of Allergy And Clinical Immunology 2025, 155: ab234. DOI: 10.1016/j.jaci.2024.12.720.

  Peer-Reviewed Original Research

  Concepts